139 related articles for article (PubMed ID: 38363374)
1. Diagnosis and staging of small intestinal neuroendocrine tumors with CT enterography and PET with Gallium-68: preoperative risk stratification protocol.
Bonomi A; Fumagalli Romario U; Funicelli L; Conti G; Realis Luc M; Ceci F; Pozzi S; Radice D; Fazio N; Bertani E
Langenbecks Arch Surg; 2024 Feb; 409(1):63. PubMed ID: 38363374
[TBL] [Abstract][Full Text] [Related]
2. Preoperative
Norlén O; Montan H; Hellman P; Stålberg P; Sundin A
World J Surg; 2018 Feb; 42(2):498-505. PubMed ID: 29159606
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
[TBL] [Abstract][Full Text] [Related]
4. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
5. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Beuschlein F; Wängler B; Uebleis C; Schmidt GP; Spitzweg C; Bartenstein P; Hacker M
Radiology; 2014 Feb; 270(2):517-25. PubMed ID: 24056402
[TBL] [Abstract][Full Text] [Related]
7. Should
Babazadeh NT; Schlund DJ; Cornelius T; Singh JS; Tierney JF; Chen M; Keutgen XM
World J Surg; 2020 Feb; 44(2):604-611. PubMed ID: 31576440
[TBL] [Abstract][Full Text] [Related]
8. The inferior performance of [
Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850
[TBL] [Abstract][Full Text] [Related]
9.
Ouvrard E; Mestier L; Boursier C; Lachachi B; Sahakian N; Chevalier E; Mikail N; Carullo J; Bando-Delaunay A; Walter T; Malouf GG; Addeo P; Poncet G; Sebag F; Lebtahi R; Goichot B; Taïeb D; Imperiale A
J Nucl Med; 2022 Dec; 63(12):1865-1870. PubMed ID: 35589408
[TBL] [Abstract][Full Text] [Related]
10. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
12. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
13. Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors.
Apitzsch J; Verburg FA; Mottaghy F; Heinzel A
Diagn Interv Radiol; 2021 Jul; 27(4):573-579. PubMed ID: 34313245
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
15. The value of
Liu KY; Goldrich DY; Ninan SJ; Filimonov A; Lam H; Govindaraj S; Iloreta AM
Head Neck; 2021 Jun; 43(6):E30-E40. PubMed ID: 33786927
[TBL] [Abstract][Full Text] [Related]
16. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
Schraml C; Schwenzer NF; Sperling O; Aschoff P; Lichy MP; Müller M; Brendle C; Werner MK; Claussen CD; Pfannenberg C
Cancer Imaging; 2013 Mar; 13(1):63-72. PubMed ID: 23466785
[TBL] [Abstract][Full Text] [Related]
17. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
19. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
20. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
